Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, GLP-1RA, Other, Topics Dec 13 | 2024CHMP Denies Mounjaro OSA Indication; FLOW Positive CHMP Opinion; New Oramed Oral Insulin Study; Diamyd and FDA Align on Accelerated Approval; Noom to Offer Metformin for Weight LossPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Dec 11 | 2024ADA/EASD 2025 Guidelines; Ro/Lilly Zepbound SDV Partnership; Tirzepatide for Addiction TreatmentPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 10 | 2024GLP1-RAs Reduce Blood Clot Risk in T2DM; Zealand Initiates Ph2b Petrelintide Obesity Trial Enrollment; NewAmsterdam Positive CETPi Ph3 HeFH DataPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Dec 09 | 2024December CHMP Agenda; Senseonics Eversense 365 Launch Updates; BioAge Discontinues Ph2 Obesity TrialPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other, Topics Dec 06 | 2024EC Approves Novo/Catalent Deal; Novo Cuts Insulin Business; Twiist AID Webinar; New Pfizer and Novo Obesity Studies; Lilly CDMO AgreementPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 05 | 2024UK Tirzepatide Rollout Plan; Lilly and Amgen Expand Manufacturing Facilities; New Novo GLP-1/GIP RA CKD and Obesity Trials; Insulet Defends US Patent from EOFlowPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 04 | 2024Zepbound Beats Wegovy in H2H Study; Novavax to Sell Manufacturing Facility to Novo; Antag $84M Series A Financing for Ph1 Obesity TrialPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other, Topics Dec 03 | 2024Metsera Initiates Ph2b MET-097 Obesity Trial; Arrowhead Files for Ph1/2a Obesity Trial Initiation; Sanofi Invests in New Beijing Insulin PlantPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Nov 27 | 2024Arrowhead CY Q3 ’24 (FY Q4 ’24) Earnings; Embecta Discontinues Patch Pump; New Medicare and Medicaid Obesity Proposal; EOFlow Wins Legal Battle in the EUPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Nov 26 | 2024Amgen MariTide Ph2 Topline Results; Alnylam sNDA Accepted for Vutrisiran with PRV; Novartis Investor EventPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Nov 22 | 2024Lexicon Strategic Update; Boston MASH Investor Event; Ypsomed to Manufacture Cargisema Pens; Pep2Tango Obesity Startup; Generic Byetta FDA ApprovalPurchase Blast
$599
Posted in: ESPR, Glucose Monitoring, Insulin Delivery, Other, Topics Nov 20 | 2024Lilly and Laekna Obesity Partnership; Viking Ph2b MASH Data; Medtronic InPen App FDA Clearance; Omnipod 5 and FreeStyle Libre 2 Plus Integration; Flagship and Ampersand Obesity Partnership; NewAmsterdam Ph3 TANDEM CV DataPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Nov 19 | 2024Dexcom and Oura Partnership; Novo ESSENCE Data at AASLD; Medtronic CY Q3 ’24 (FY Q2 ’25) Earnings; Silence, Esperion, NewAmsterdam, and Arrowhead Data at AHA 2024; Aligos Ph2 MASH Data; Biomea COVALENT-111 AnalysisPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, SGLT2i, Topics Nov 18 | 2024Lilly Releases HFpEF and Lp(a) Data; Inventiva and Sagimet MASH Data at AASLD; New Abbott Manufacturing Facility; NeuroBo Name ChangePurchase Blast
$599
Posted in: Other, Topics Nov 15 | 2024Boston Pharmaceuticals Ph2a MASH Topline ResultsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Nov 14 | 2024Tirzepatide Full Surmount-1 Three-Year Results; Novo to Discontinue Human Insulin Pens; Hims & Hers Launches GLP-1RA Shortage Tracker; Skye Enrollment UpdatePurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Nov 14 | 2024New Zepbound DTC Observed; New Novo Insulin Trial; Amgen Damage Control; Lexicon, Fractyl, and Terns Q3 ‘24 Earnings; Metsera Series B Financing; G&L Oral GLP-1RA DataPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Nov 12 | 2024AZ, Altimmune, and Scholar Rock Q3 ’24 Earnings; New Ph2 Lilly Trial ObservedPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Topics Nov 11 | 2024November CHMP AgendaPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
